214759-65-6

Basic information

• Product Name: 6-CYANO-4-CHROMANONE
• Synonyms: 6-CYANO-4-CHROMANONE;4-oxochroman-7-carbonitrile;2H-1-Benzopyran-7-carbonitrile,3,4-dihydro-4-oxo-;4-oxochroman-7-carbonitrile(WX683304)
• CAS NO: 214759-65-6
• Molecular Formula: C₁₀H₇NO₂
• Molecular Weight: 173.17
• Mol File: 214759-65-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 359.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 6-CYANO-4-CHROMANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CYANO-4-CHROMANONE(214759-65-6)
• EPA Substance Registry System: 6-CYANO-4-CHROMANONE(214759-65-6)

Safety Data

• Hazardous Substances Data: 214759-65-6(Hazardous Substances Data)

Usage

General Description

6-CYANO-4-CHROMANONE is an organic compound with the molecular formula C10H7NO2. It is a member of the chromanone family, which is known for its diverse range of biological activities. This specific chemical has been studied for its potential as an anti-inflammatory and antioxidant agent. It has also shown promise in inhibiting cell proliferation and inducing apoptosis in cancer cells. Additionally, 6-CYANO-4-CHROMANONE has been found to have neuroprotective effects and may be useful in the treatment of neurodegenerative diseases. Its unique chemical structure and potential therapeutic properties make it an exciting target for further research and development in the field of medicinal chemistry.

Upstream product

• 151-50-8 potassium cyanide 
• 151884-08-1 4-oxochroman-7-yl trifluoromethanesulfonate 
• 557-21-1 zinc(II) cyanide 
• 18442-22-3 7-Bromo-2,3-dihydro-4H-chromen-4-one 

Downstream Products

• 1374445-39-2 (4R,5S)-3-((1S,3R)-3-((3R,4S)-4-hydroxy-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)chroman-3-ylamino)cyclohexanecarbonyl)-4-methyl-5-phenyloxazolidin-2-one 
• 1374445-42-7 (4R,5S)-3-((1S,3S)-3-((3R,4S)-4-hydroxy-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)chroman-3-ylamino)cyclohexanecarbonyl)-4-methyl-5-phenyloxazolidin-2-one 
• 1374444-83-3 (1S,3S)-3-((3R,4S)-4-hydroxy-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)chroman-3-ylamino)cyclohexanecarboxylic acid trifluoroacetate 
• 1374443-90-9 tert-butyl (3S,4R)-4-hydroxy-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)chroman-3-ylcarbamate 
• 1374443-91-0 tert-butyl (3R,4S)-4-hydroxy-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)chroman-3-ylcarbamate 
• 1374443-93-2 (3S,4R)-3-amino-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)chroman-4-ol trifluoroacetate 
• 1374443-95-4 (3R,4S)-3-amino-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)chroman-4-ol trifluoroacetate 

Relevant articles and documents

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy

Mutations in the Leucine Rich Repeat Protein Kinase 2 gene (LRRK2) are the most common genetic causes of Parkinson's Disease (PD). The G2019S mutation is the most common inherited LRRK2 mutation, occurs in the kinase domain, and results in increased kinase activity. We report the discovery and development of compound 38, an indazole-based, G2019S-selective (>2000-fold vs. WT) LRRK2 inhibitor capable of entering rodent brain (Kp = 0.5) and selectively inhibiting G2019S-LRRK2. The compounds disclosed herein present a starting point for further development of brain penetrant G2019S selective inhibitors that hopefully reduce lung phenotype side-effects and pave the way to providing a precision medicine for people with PD who carry the G2019S mutation.

HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.

BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF

Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and